Premium
Sphingosine kinase 1–interacting protein is a dual regulator of insulin and incretin secretion
Author(s) -
Liu Yanyan,
Harashima ShinIchi,
Wang Yu,
Suzuki Kazuyo,
Tokumoto Shinsuke,
Usui Ryota,
Tatsuoka Hisato,
Tanaka Daisuke,
Yabe Daisuke,
Harada Norio,
Hayashi Yoshitaka,
Inagaki Nobuya
Publication year - 2019
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.201801783rr
Subject(s) - medicine , endocrinology , incretin , insulin , gastric inhibitory polypeptide , biology , type 2 diabetes , sphingosine kinase , secretion , sphingosine , insulin resistance , protein kinase a , proinflammatory cytokine , inflammation , kinase , chemistry , diabetes mellitus , receptor , glucagon , sphingosine 1 phosphate , microbiology and biotechnology
Our previous study demonstrated that sphingosine kinase 1–interacting protein (SKIP, or Sphkap) is expressed in pancreatic β‐cells, and depletion of SKIP enhances glucose‐stimulated insulin secretion. We find here that SKIP is also expressed in intestinal K‐ and L‐cells and that secretion of gastric inhibitory polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) as well as insulin are significantly increased, and blood glucose levels are decreased in SKIP‐deficient (SKIP −/− ) mice compared with those in wild‐type mice. Plasma triglyceride (Tg), LDL cholesterol, and mRNA levels of proinflammatory cytokines in adipose tissues, livers, and intestines were found to be significantly decreased in SKIP −/− mice. The phenotypic characteristics of SKIP −/− mice, including adiposity and attenuation of basal inflammation, were abolished by genetic depletion of GIP. The improvement of glucose tolerance and lipid profiles in SKIP −/− mice were cancelled by GLP‐1 receptor antagonist exendin‐(9–39) treatment. In summary, depletion of SKIP ameliorates glucose tolerance by enhancing secretion of insulin and incretins, improves lipid metabolism, and reduces basal inflammation levels. Thus, inhibition of SKIP action may emerge as a new option for treatment of type 2 diabetes mellitus with metabolic dysfunction.—Liu, Y., Harashima, S., Wang, Y., Suzuki, K., Tokumoto, S., Usui, R., Tatsuoka, H., Tanaka, D., Yabe, D., Harada, N., Hayashi, Y., Inagaki, N. Sphingosine kinase 1–interacting protein is a dual regulator of insulin and incretin secretion. FASEB J. 33, 6239–6253 (2019). www.fasebj.org